162 related articles for article (PubMed ID: 22375924)
21. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
22. ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer.
Zhang Z; Yamashita H; Toyama T; Sugiura H; Ando Y; Mita K; Hamaguchi M; Kawaguchi M; Miura Y; Iwase H
Clin Cancer Res; 2005 Jan; 11(1):193-8. PubMed ID: 15671546
[TBL] [Abstract][Full Text] [Related]
23. Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients.
Yan Y; Skliris GP; Penner C; Chooniedass-Kothari S; Cooper C; Nugent Z; Blanchard A; Watson PH; Myal Y; Murphy LC; Leygue E
Breast Cancer Res; 2009; 11(5):R67. PubMed ID: 19740422
[TBL] [Abstract][Full Text] [Related]
24. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
[TBL] [Abstract][Full Text] [Related]
25. Molecular characterization of the DYX1C1 gene and its application as a cancer biomarker.
Kim YJ; Huh JW; Kim DS; Bae MI; Lee JR; Ha HS; Ahn K; Kim TO; Song GA; Kim HS
J Cancer Res Clin Oncol; 2009 Feb; 135(2):265-70. PubMed ID: 18618141
[TBL] [Abstract][Full Text] [Related]
26. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.
Anders CK; Hsu DS; Broadwater G; Acharya CR; Foekens JA; Zhang Y; Wang Y; Marcom PK; Marks JR; Febbo PG; Nevins JR; Potti A; Blackwell KL
J Clin Oncol; 2008 Jul; 26(20):3324-30. PubMed ID: 18612148
[TBL] [Abstract][Full Text] [Related]
27. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
[TBL] [Abstract][Full Text] [Related]
28. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
[TBL] [Abstract][Full Text] [Related]
29. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
30. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
31. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer.
Baquero MT; Hanna JA; Neumeister V; Cheng H; Molinaro AM; Harris LN; Rimm DL
Cancer; 2012 Oct; 118(19):4660-9. PubMed ID: 22359235
[TBL] [Abstract][Full Text] [Related]
32. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G
Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280
[TBL] [Abstract][Full Text] [Related]
33. Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients.
van Nes JG; de Kruijf EM; Putter H; Faratian D; Munro A; Campbell F; Smit VT; Liefers GJ; Kuppen PJ; van de Velde CJ; Bartlett JM
Breast Cancer Res Treat; 2012 May; 133(1):49-59. PubMed ID: 21796367
[TBL] [Abstract][Full Text] [Related]
34. No evidence for association between dyslexia and DYX1C1 functional variants in a group of children and adolescents from Southern Italy.
Bellini G; Bravaccio C; Calamoneri F; Donatella Cocuzza M; Fiorillo P; Gagliano A; Mazzone D; del Giudice EM; Scuccimarra G; Militerni R; Pascotto A
J Mol Neurosci; 2005; 27(3):311-4. PubMed ID: 16280601
[TBL] [Abstract][Full Text] [Related]
35. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy.
Bieche I; Parfait B; Le Doussal V; Olivi M; Rio MC; Lidereau R; Vidaud M
Cancer Res; 2001 Feb; 61(4):1652-8. PubMed ID: 11245479
[TBL] [Abstract][Full Text] [Related]
36. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
37. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.
Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z
BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458
[TBL] [Abstract][Full Text] [Related]
38. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
[TBL] [Abstract][Full Text] [Related]
39. NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.
Wan L; Liu T; Hong Z; Pan Y; Sizemore ST; Zhang J; Ma Z
Breast Cancer Res; 2019 Dec; 21(1):148. PubMed ID: 31856858
[TBL] [Abstract][Full Text] [Related]
40. Genetic variant in KIAA0319, but not in DYX1C1, is associated with risk of dyslexia: an integrated meta-analysis.
Zou L; Chen W; Shao S; Sun Z; Zhong R; Shi J; Miao X; Song R
Am J Med Genet B Neuropsychiatr Genet; 2012 Dec; 159B(8):970-6. PubMed ID: 23065966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
